APOB and familial hypercholesterolemia: There was a trend toward a higher proportion of APOB mutations in the CVD group (20% vs 6.7%), indicating that even the “milder” familial hypercholesterolemia from APOB variants can lead to premature CVD if not adequately treated or if other risk factors are present.